Loading...
•
Dec 31, 2023
Jazz Pharmaceuticals Q4 2023 Earnings Report
Jazz Pharmaceuticals announced its Q4 2023 financial results, demonstrating revenue growth and strategic pipeline advancements.
Key Takeaways
Jazz Pharmaceuticals reported a strong Q4 2023, achieving its first $1 billion revenue quarter, driven by key growth drivers like Xywav, Epidiolex, and Rylaze. The company's oncology revenue surpassed $1 billion in 2023, and they anticipate multiple late-stage pipeline catalysts in 2024.
Achieved first $1 billion revenue quarter.
Xywav net product sales increased 20% year-over-year in Q4 2023.
Epidiolex/Epidyolex net product sales increased 16% year-over-year in Q4 2023.
Rylaze net product sales increased 26% year-over-year in Q4 2023.
Revenue by Segment
Forward Guidance
Jazz Pharmaceuticals provided full year 2024 financial guidance, expecting revenues between $4.0 and $4.2 billion. Neuroscience revenue is projected between $2.8 and $2.95 billion, and Oncology revenue between $1.12 and $1.22 billion.
Positive Outlook
- Total revenue guidance of $4.0 to $4.2 billion.
- Neuroscience revenue guidance of $2.8 to $2.95 billion.
- Oncology revenue guidance of $1.12 to $1.22 billion.
- Non-GAAP gross margin % of 93%
- Non-GAAP net income between $1.275 and $1.350 billion
Challenges Ahead
- GAAP Gross margin % of 89%
- GAAP SG&A expenses between $1.346 and $1.426 billion.
- GAAP R&D expenses between $877 and $935 million.
- GAAP Effective tax rate between (22)% and (3)%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...